Stevanato Group (NYSE:STVN) announced today that it will begin construction on a new U.S. facility in Fishers, Indiana. Piombino Dese, Italy-based Stevanato Group will begin construction on the new facility this month with expectations for the site to be operational in 2023. According to a news release, constructing the new facility falls in line with […]
Stevanato Group
Stevanato Group brings in upsized IPO worth $453.5M
Stevanato Group announced today that the underwriters of its recently completed initial public offering purchased more than 1 million additional shares. The option exercised by the underwriters saw the acquisition of an additional 1,018,280 ordinary Stevanato Group shares at $21 per share. Piombino Dese, Italy–based Stevanato Group’s IPO resulted in net proceeds of approximately $453.5 […]
Bexson Biomedical wins U.S. patent for ketamine formulation
Bexson Biomedical announced that the U.S. Patent and Trademark Office (USPTO) granted a patent for its BB106 ketamine therapy. Santa Barbara, Calif.-based Bexson’s patent describes pharmaceutical formulations and treatment methods for the ketamine therapy, which the company believes allows for safety, comfort and pharmacokinetics that improve the administration of ketamine through multiple avenues, including the […]
Haselmeier licenses Axis-D pen injector to Stevanato Group
Haselmeier said today that it entered into an exclusive agreement with Stevanato Group to license the Axis-D pen injector and intellectual property for the development, manufacturing and supply of the device for diabetes care. Haselmeier’s Axis-D auto-injector pen is approved for use by the European Medical Agency and the FDA, among other regulatory bodies. The […]
